Doneddu, P, Asselta, R, Manganelli, F, Cocito, D, Inghilleri, M, Ricciardi, D, Cavaletti, G, Di Stefano, V, Filosto, M, Carta, A, Vegezzi, E, Matà, S, Habetswallner, F, Farotti, L, Luigetti, M, Ruiu, E, Mataluni, G, Falzone, Y, Carpo, M, Leonardi, L, Gentile, L, Ripellino, P, Peric, S, Basta, I, Querol, L, Jacobs, B, Eftimov, F, Orazio, EN. DISSECTING THE GENETIC ARCHITECTURE OF CIDP. STUDY PROTOCOL FOR AN INTERNATIONAL COLLABORATIVE GENOME-WIDE ASSOCIATION STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Allen, J, Van Doorn, PA, Basta, I, Dysgaard, T, Eggers, C, Guptill, J, Gwathmey, K, Hewamadduma, C, Hofman, E, Hussain, Y, Kuwabara, S, Le Masson, G, Leypoldt, F, Lin, J, Lipowska, M, Lowe, M, Pinter, GL, Querol, L, Simu, MA, Chang, T, Tse, A, Ulrichts, P, Van Hoorick, B, Yamasaki, R, Lewis, RA. EFFICACY AND SAFETY OF SUBCUTANEOUS (SC) EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIALS. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2024; 29DOI:. PMID:. IF:3.200(Q2/4D).

Martínez-Martínez, L, Lacruz, AC, Querol, L, Cortés-Vicente, E, Pascual, E, Rojas-García, R, Reyes-Leiva, D, Alvaro, Y, Moltó, E, Ortiz, E, Gallardo, E, Juárez, C, Mariscal, A. Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis. JOURNAL OF NEUROLOGY. 2024; 271(7)DOI:10.1007/s00415-024-12317-0. PMID:38578496. IF:4.600(Q1/2D).

Cortés-Vicente, E, Schreiner, B, Saccà, F, Narayanaswami, P. Editorial: New perspectives in the treatment of myasthenia gravis. Frontiers in Neurology. 2024; 15DOI:10.3389/fneur.2024.1418631. PMID:38919972. IF:2.800(Q2/5D).

Saccà, F, Salort-Campana, E, Jacob, S, Cortés-Vicente, E, Schneider-Gold, C. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. EUROPEAN JOURNAL OF NEUROLOGY. 2024; 31(6)DOI:10.1111/ene.16180. PMID:38117543. IF:3.900(Q1/3D).

Tawil, R, Wagner, KR, Hamel, J, Leung, DG, Statland, JM, Wang, LH, Genge, A, Sacconi, S, Lochmüller, H, Reyes-Leiva, D, Diaz-Manera, J, Alonso-Perez, J, Muelas, N, Vilchez, JJ, Pestronk, A, Gibson, S, Goyal, NA, Hayward, LJ, Johnson, N, LoRusso, S, Freimer, M, Shieh, PB, Subramony, SH, van Engelen, B, Kools, J, Leinhard, OD, Widholm, P, Morabito, C, Moxham, CM, Cadavid, D, Mellion, ML, Odueyungbo, A, Tracewell, WG, Accorsi, A, Ronco, L, Gould, RJ, Shoskes, J, Rojas, LA, Jiang, JG. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. LANCET NEUROLOGY. 2024; 23(5)DOI:10.1016/S1474-4422(24)00073-5. PMID:38631764. IF:45.500(Q1/1D).